We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,338 hedge funds and large institutions have $84.7B invested in Bristol-Myers Squibb in 2024 Q1 according to their latest regulatory filings, with 175 funds opening new positions, 937 increasing their positions, 968 reducing their positions, and 176 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more call options, than puts

Call options by funds: $1.56B | Put options by funds: $1.23B

6% more capital invested

Capital invested by funds: $79.7B → $84.7B (+$4.96B)

0.89% more ownership

Funds ownership: 76.35%77.24% (+0.89%)

1% less first-time investments, than exits

New positions opened: 175 | Existing positions closed: 176

3% less repeat investments, than reductions

Existing positions increased: 937 | Existing positions reduced: 968

1% less funds holding

Funds holding: 2,3652,338 (-27)

17% less funds holding in top 10

Funds holding in top 10: 2420 (-4)

Holders
2,338
Holders Change
-27
Holders Change %
-1.14%
% of All Funds
33.6%
Holding in Top 10
20
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-16.67%
% of All Funds
0.29%
New
175
Increased
937
Reduced
968
Closed
176
Calls
$1.56B
Puts
$1.23B
Net Calls
+$326M
Net Calls Change
-$171M

BMY Hedge Fund Activity: Q1 2024 in Review

2,338 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q1 2024, worth a combined $84.7B — up 6.2% from $79.7B a quarter earlier.

Sellers outnumbered buyers: 176 funds closed out of BMY and 175 opened new positions — a net loss of 1 holder — while 968 trimmed existing stakes and 937 added.

The largest buyer was Charles Schwab, adding an estimated $2.16B. The largest seller was Vanguard Group, cutting an estimated $616M.

  • 2,338 institutional investors held Bristol-Myers Squibb (BMY) as of Q1 2024, down from 2,365 in Q4 2023.
  • Funds reported $84.7B of Bristol-Myers Squibb stock for Q1 2024, up 6.2% quarter-over-quarter.
  • 175 funds opened new Bristol-Myers Squibb positions in Q1 2024 and 176 closed out, a net change of -1 holder.
  • The largest Bristol-Myers Squibb buyer in Q1 2024 was Charles Schwab, an estimated $2.16B added.
  • The largest Bristol-Myers Squibb seller in Q1 2024 was Vanguard Group, an estimated $616M sold.

Based on aggregated 13F filings for Q1 2024.